Table 1.
Subjects.
| Disease | N | Age | Male | PAVTE | ACI | ACS | DIC | TMA | Mortality |
|---|---|---|---|---|---|---|---|---|---|
| Hepatocellular carcinoma * | 23 | 73.4 ± 6.9 | 18 | 3 | 2 | 1 | 0 | 0 | 0 (0%) |
| Colon cancer * | 4 | 74.8 ± 11.2 | 3 | 1 | 0 | 0 | 0 | 0 | 0 (0%) |
| Stomach cancer #,&,+ | 8 | 76.6 ± 9.6 | 8 | 0 | 1 | 0 | 1 | 1 | 3 (37.5%) |
| Prostate cancer # | 5 | 80.4 ± 5.9 | 5 | 1 | 1 | 0 | 0 | 0 | 1 # (20.0%) |
| Biliary tract cancer & | 7 | 79.3 ± 6.4 | 3 | 1 | 0 | 0 | 0 | 0 | 1 (14.3%) |
| Lung cancer + | 6 | 70.3 ± 11.0 | 6 | 0 | 0 | 0 | 0 | 0 | 1 + (16.7%) |
| Pancreatic cancer | 10 | 67.6 ± 10.3 | 7 | 1 | 1 | 0 | 0 | 0 | 2 (20.0%) |
| Esophageal cancer | 4 | 65.8 ± 10.7 | 4 | 0 | 1 | 0 | 0 | 0 | 0 (0%) |
| Malignant lymphoma | 14 | 77.4 ± 6.0 | 8 | 2 | 1 | 2 | 0 | 0 | 1 (7.1%) |
| Myelodysplastic syndrome | 10 | 78.2 ± 11.3 | 4 | 1 | 0 | 0 | 1 | 0 | 0 (0%) |
| Others | 5 | 67.7 ± 9.4 | 2 | 2 | 0 | 1 | 0 | 0 | 0 (0%) |
| Total | 96 | 73.9 ± 9.3 | 68 | 12 | 7 | 4 | 2 | 1 | 9 (9.4%) |
*, a patient with hepatocellular carcinoma and colon cancer; #, a patient with stomach and prostate cancer; &, a patient with stomach and biliary tract cancer; +, a patient with stomach and lung cancer; PAVTE, peripheral arterial and venous thromboembolism, ACI, acute cerebral infarction; ACS, acute coronary syndrome; DIC, disseminated intravascular coagulation; TMA, thrombotic microangiopathic anemia.